Get the Stockscreener App
31.53
0.13%
0.04
Arrivent Biopharma Inc stock is traded at $31.53, with a volume of 19,681.
It is up +0.13% in the last 24 hours and up +15.67% over the past month.
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$31.49
Open:
$31.43
24h Volume:
19,681
Relative Volume:
0.08
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.99%
1M Performance:
+15.67%
6M Performance:
+83.00%
1Y Performance:
+0.00%
1-Day Range:
$31.07
$32.00
1-Week Range:
$28.50
$32.01
52-Week Range:
$14.35
$32.40
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Arrivent Biopharma Inc Stock (AVBP) Latest News
AlphaCentric Advisors LLC Sells 71,000 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Long Term Trading Analysis for (AVBP) - Stock Traders Daily
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month HighShould You Buy? - MarketBeat
ArriVent To Present FURTHER Data At The 2024 World Conference On Lung Cancer - RTTNews
When the Price of (AVBP) Talks, People Listen - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 80.1% in September - MarketBeat
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc - Yahoo Finance
(AVBP) Proactive Strategies - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3% - MarketBeat
Novo Holdings A S Buys 422,860 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.4% in September - MarketBeat
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4% - MarketBeat
How to Take Advantage of moves in (AVBP) - Stock Traders Daily
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Simply Wall St
Bank of New York Mellon Corp Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - MarketBeat
It makes sense and dollars to buy ArriVent BioPharma Inc. (AVBP) stock - SETE News
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94 - Defense World
Was ArriVent BioPharma Inc. (AVBP)’s session last reading good? - US Post News
Closing Figures: ArriVent BioPharma Inc. (AVBP)’s Positive Finish at 24.20, Up 2.59 - The Dwinnex
ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Given Outperform Rating at Oppenheimer - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - Defense World
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com Canada
ArriVent BioPharma stock target raised on positive trial results By Investing.com - Investing.com Canada
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Should investors be concerned about ArriVent BioPharma Inc. (AVBP)? - US Post News
Analyst boosts ArriVent BioPharma shares price target after promising trial data - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - MarketBeat
ArriVent reports promising data on lung cancer drug firmonertinib - Investing.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - ForexTV.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib - The Bakersfield Californian
ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher - MarketBeat
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance
ArriVent, lung cancer drug developer, files for $100M IPO - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4% - MarketBeat
ArriVent BioPharma Inc. Inc. (AVBP) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month High at $26.24 - MarketBeat
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - Quantisnow
Arrivent Biopharma Inc Stock (AVBP) Financials Data
There is no financial data for Arrivent Biopharma Inc (AVBP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Arrivent Biopharma Inc Stock (AVBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMEN | 10% Owner |
Jan 30 '24 |
Buy |
18.00 |
555,555 |
9,999,990 |
4,484,672 |
| ORBIMED ADVISORS LLC | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| GORDON CARL L | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| HEALY JAMES | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,696,752 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):